JPWO2019161505A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019161505A5 JPWO2019161505A5 JP2020544653A JP2020544653A JPWO2019161505A5 JP WO2019161505 A5 JPWO2019161505 A5 JP WO2019161505A5 JP 2020544653 A JP2020544653 A JP 2020544653A JP 2020544653 A JP2020544653 A JP 2020544653A JP WO2019161505 A5 JPWO2019161505 A5 JP WO2019161505A5
- Authority
- JP
- Japan
- Prior art keywords
- boost
- antigenic protein
- prime
- immune response
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000890 antigenic effect Effects 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
Claims (1)
- 哺乳動物対象において免疫応答を誘導することにおける使用のためのプライム：ブーストワクチンであって、
ａ．前記プライムが、哺乳動物において免疫応答を生じさせることができる少なくとも１つの抗原タンパク質を含み；
ｂ．前記ブーストが、哺乳動物において免疫応答を誘導するように製剤化された腫瘍溶解性ウイルス及び少なくとも１つの抗原タンパク質を含み；
前記プライムの前記少なくとも１つの抗原タンパク質及び前記ブーストの前記少なくとも１つの抗原タンパク質が同じ腫瘍抗原由来であり、
前記ブーストの前記少なくとも１つの抗原タンパク質が前記ブーストの前記ウイルスによってコードされていない、使用のためのプライム：ブーストワクチン。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024034921A JP2024069347A (ja) | 2018-02-22 | 2024-03-07 | アジュバントとしての腫瘍溶解性ウイルス |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633883P | 2018-02-22 | 2018-02-22 | |
| US62/633,883 | 2018-02-22 | ||
| US201862751091P | 2018-10-26 | 2018-10-26 | |
| US62/751,091 | 2018-10-26 | ||
| PCT/CA2019/050220 WO2019161505A1 (en) | 2018-02-22 | 2019-02-22 | Oncolytic viruses as adjuvants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034921A Division JP2024069347A (ja) | 2018-02-22 | 2024-03-07 | アジュバントとしての腫瘍溶解性ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514381A JP2021514381A (ja) | 2021-06-10 |
| JPWO2019161505A5 true JPWO2019161505A5 (ja) | 2022-02-24 |
| JP7454320B2 JP7454320B2 (ja) | 2024-03-22 |
Family
ID=67686712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544653A Active JP7454320B2 (ja) | 2018-02-22 | 2019-02-22 | アジュバントとしての腫瘍溶解性ウイルス |
| JP2024034921A Pending JP2024069347A (ja) | 2018-02-22 | 2024-03-07 | アジュバントとしての腫瘍溶解性ウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034921A Pending JP2024069347A (ja) | 2018-02-22 | 2024-03-07 | アジュバントとしての腫瘍溶解性ウイルス |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200397892A1 (ja) |
| EP (1) | EP3755369A4 (ja) |
| JP (2) | JP7454320B2 (ja) |
| CN (1) | CN112399855A (ja) |
| CA (1) | CA3091969A1 (ja) |
| WO (1) | WO2019161505A1 (ja) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0105606D0 (en) * | 2001-03-07 | 2001-04-25 | Cantab Pharmaceuticals Res Ltd | Immunogens and vaccines and their preparation and use |
| BRPI0518146A (pt) * | 2004-10-14 | 2008-10-28 | Crucell Holland Bv | kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária |
| BRPI0808553A2 (pt) * | 2007-03-02 | 2014-08-19 | Glaxosmithkline Biolog Sa | Métodos para elevar uma resposta imune contra um patógeno, para estimar a produção de células t cd4+ e/ou cd8+ e/ou anticorpos específicos de patógeno em mamíferos e para estimular uma resposta imune em um mamífero, composição de vacina, uso da mesma, e, kit |
| CA2734740A1 (en) | 2008-08-21 | 2010-02-25 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
| WO2010105347A1 (en) * | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
| EP2780034A1 (en) * | 2011-11-14 | 2014-09-24 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
| US10363293B2 (en) * | 2013-02-21 | 2019-07-30 | Turnstone Limited Partnership | Vaccine composition |
| ES2714921T3 (es) * | 2014-05-19 | 2019-05-30 | Valo Therapeutics Oy | Adenovirus oncolíticos recubiertos para vacunas contra el cáncer |
| WO2016025295A1 (en) * | 2014-08-06 | 2016-02-18 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| CN109415705A (zh) * | 2016-05-09 | 2019-03-01 | 图恩斯通有限合伙公司 | 组合初免:加强免疫疗法 |
-
2019
- 2019-02-22 WO PCT/CA2019/050220 patent/WO2019161505A1/en unknown
- 2019-02-22 EP EP19756747.2A patent/EP3755369A4/en active Pending
- 2019-02-22 JP JP2020544653A patent/JP7454320B2/ja active Active
- 2019-02-22 US US16/971,285 patent/US20200397892A1/en active Pending
- 2019-02-22 CA CA3091969A patent/CA3091969A1/en active Pending
- 2019-02-22 CN CN201980027179.0A patent/CN112399855A/zh active Pending
-
2023
- 2023-04-26 US US18/307,593 patent/US20230285552A1/en active Pending
-
2024
- 2024-03-07 JP JP2024034921A patent/JP2024069347A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525085A5 (ja) | ||
| WO2020060403A3 (en) | African swine fever virus vaccine | |
| JP2005523318A5 (ja) | ||
| JP2014502156A5 (ja) | ||
| JP2021035983A5 (ja) | ||
| JP2017507117A5 (ja) | ||
| JP2014503206A5 (ja) | ||
| JP2015533841A5 (ja) | ||
| JP2012501959A5 (ja) | ||
| JP2017515508A5 (ja) | ||
| JP2015524422A5 (ja) | ||
| JP2017526689A5 (ja) | ||
| JP2009522368A5 (ja) | ||
| JP2006504644A5 (ja) | ||
| Kianmehr et al. | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice | |
| WO2022140364A3 (en) | African swine fever (asf) virus vaccines | |
| Saeedi et al. | Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice | |
| Zhang et al. | Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice | |
| Sautto et al. | Next generation vaccines for infectious diseases | |
| Pishraft-Sabet et al. | Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96 | |
| MX2022007398A (es) | Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas. | |
| JP2016528176A5 (ja) | ||
| Ozkan | How close are we to a Covid-19 vaccine | |
| JPWO2019161505A5 (ja) | ||
| Guan et al. | Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes |